The LMNA-CK2α-STING axis suppresses innate immune activation at the nuclear envelope, and pharmacologic STING inhibition rescues progeroid phenotypes and extends lifespan in progeroid mouse models, with controlled attenuation rather than complete elimination of STING signaling driving therapeutic efficacy.
Lamin A/C (LMNA) serves as a critical nuclear envelope scaffold that recruits both STING and CK2α to the nuclear envelope.
CK2α phosphorylates STING at Ser366, which promotes STING turnover and restricts its accumulation at the nuclear envelope.
Pharmacologic STING inhibition in vivo robustly rescues progeroid phenotypes including loss of bone density and multi-tissue senescence.
Constitutive STING ablation yields limited survival benefits compared to pharmacologic STING inhibition.
Myeloid-specific CK2α ablation induces premature aging phenotypes that are rescued by STING inhibition.
Chronic activation of the cGAS-STING pathway driven by nuclear envelope barrier failure is a key trigger of inflammaging and cellular senescence.
The LMNA-CK2α-STING axis represents a key biochemical mechanism suppressing innate immune activation at the nuclear envelope.
This research suggests that a specific molecular pathway involving three proteins—lamin A/C (LMNA), an enzyme called CK2α, and an immune signaling protein called STING—plays a central role in how cells age. Under normal conditions, LMNA acts as a structural scaffold at the nucleus's outer membrane, holding CK2α and STING close together so that CK2α can chemically tag STING for disposal. This tagging keeps STING levels low, preventing the immune system from becoming chronically overactivated. As cells age or in diseases of accelerated aging (progeroid syndromes), this system breaks down, STING accumulates, and persistent low-grade inflammation (called 'inflammaging') sets in, driving tissue deterioration across the body. The study further found that a drug called H-151, which inhibits STING, could rescue major aging symptoms in mouse models of accelerated aging—including bone loss and cellular senescence across multiple organs—and extended the animals' lifespans. Importantly, completely eliminating STING genetically provided much weaker benefits than partially suppressing it with the drug. This suggests that the goal should be to dial down excessive STING activity rather than eliminate it entirely, since some STING signaling appears to be necessary for normal health. These findings matter because they identify a specific, druggable molecular mechanism linking nuclear structural failure to chronic immune activation in aging. The research suggests that targeting the STING pathway pharmacologically—particularly with approaches that modulate rather than abolish its activity—could be a viable strategy for treating age-related diseases and potentially conditions of premature aging. The identification of the LMNA-CK2α-STING axis also provides a clearer picture of why nuclear envelope deterioration, a hallmark of aging cells, translates into body-wide inflammation.
Zhang J, Jin M, Rao D, Wang M, Wang J, Ma C, et al.. (2026). CK2α restriction of STING accumulation underlies systemic aging.. Nature communications. https://doi.org/10.1038/s41467-026-76351-4